Bioalmanac
ACE-031
ACVR2B-Fc · ActRIIB-IgG1 · Soluble activin receptor type IIB · Ramatercept
A myostatin trap that reached phase 2 in Duchenne muscular dystrophy and was stopped there. The muscle effects were real but never reached significance; the reason it stopped was nosebleeds and spider veins.
Storage
- Freeze-dried powder
- Refrigerated at 2–8 °C, protected from light. Do not freeze the clinical formulation.
- After mixing
- Refrigerated at 2–8 °C. Proteins of this size are more fragile than short peptides — avoid shaking, which denatures them.
- Long-term, frozen
- Repeated freezing and thawing damages proteins of this class.
Dose ranges reported in sources
Descriptions of what sources report, not recommendations.
| Goal | Range | Frequency | Source |
|---|---|---|---|
| Dose used in the phase 2 trial | 1000–3000 mcg | Every 2 to 4 weeks | Clinical trial |
When to stop
- Any nosebleed, bleeding gums, or unusual bruising.
- New small dilated vessels appearing in the skin.
- Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
- Note that stopping does not clear it quickly. The half-life is measured in weeks.
Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.